阻断肿瘤内在TGFβ信号驱动小细胞肺癌超进展
在bintrafusp alfa(PD-L1/TGFβ双功能抑制剂)治疗小细胞肺癌的临床试验中,34例可评估患者18%部分缓解、20%疾病稳定、62%疾病进展,进展者中38%符合超进展标准。血液和肿瘤分析显示超进展与全身免疫抑制及TGFβ信号升高相关,功能研究证实肿瘤内在TGFβ信号抑制部分SCLC增殖,通路阻断触发超增殖。外部验证确认TGFβ高转录状态与较差生存相关。
要点
- bintrafusp alfa治疗SCLC的HPD发生率达38%,高于PD-(L)1单药。
- 肿瘤内在TGFβ信号在部分SCLC中起生长限制作用,阻断后触发超增殖。
- TGFβ高间质转录状态与较差生存相关,支持生物标志物指导用药。
核心结论
- 肿瘤内在TGFβ信号在SCLC中具有背景依赖的生长限制功能,阻断该通路可驱动超进展。
研究设计与样本
- bintrafusp alfa治疗小细胞肺癌的临床试验,34例可评估患者。
- 跨其他肿瘤类型(n=450)比较bintrafusp alfa与PD-(L)1阻断的超进展频率。
- 功能研究及细胞系和肿瘤样本的外部验证。
主要发现
- 34例可评估患者中18%部分缓解、20%疾病稳定、62%疾病进展。
- 进展者中38%符合超进展疾病(HPD)标准。
- HPD在其他肿瘤类型(n=450)中亦观察到,bintrafusp alfa频率高于PD-(L)1单药。
- HPD与全身免疫抑制及TGFβ信号升高相关。
- 肿瘤内在TGFβ信号抑制部分SCLC增殖,通路阻断触发超增殖。
关键数值与推荐
- HPD标准:38%的进展者符合。
- 外部验证:TGFβ高转录状态与较差生存相关。
临床怎么用
- 靶向基质免疫抑制通路时需考虑肿瘤内在TGFβ信号状态,避免在TGFβ高表达患者中诱发超进展。
- 建议以肿瘤内在生物标志物指导TGFβ靶向免疫治疗的使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Stromal immunosuppressive pathways are key modulators of response to immune checkpoint inhibitors, but the tumor-intrinsic consequences of blocking these pathways remain incompletely defined. We conducted a clinical trial of bintrafusp alfa, a bifunctional PD-L1/TGFβ inhibitor, in small cell lung cancer (SCLC). Among 34 evaluable patients, 18% had partial responses, 20% stable disease, and 62% progressive disease; 38% of progressors met the criteria for hyperprogressive disease (HPD). HPD was also observed across other tumor types (n = 450), in higher frequencies with bintrafusp alfa than PD-(L)1 blockade alone. Blood and tumor profiling showed that HPD correlated with systemic immune suppression and elevated TGFβ signaling. Functional studies demonstrated that tumor-intrinsic TGFβ signaling restrains proliferation in a subset of SCLC; pathway blockade triggers hyperproliferation. External validation across cell lines and tumor samples confirmed a tumor-intrinsic TGFβ-high transcriptional state associated with inferior survival. These findings identify a context-dependent, growth-constraining function of TGFβ and support tumor-intrinsic biomarker guidance while targeting stromal immunosuppressive pathways. SIGNIFICANCE: This study identifies tumor-intrinsic TGFβ signaling as a context-dependent growth restraint in SCLC and a driver of HPD following TGFβ blockade. A reproducible TGFβ-high mesenchymal state is linked to inferior survival, supporting biomarker-guided use of TGFβ-targeted immunotherapy.
引用
- Schroeder BA, Mohindroo C, Meinhardt AL, et al. Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer. Cancer Discov. 2026. PMID: 42018154. doi:10.1158/2159-8290.CD-25-1454
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。